Subsequently, a long-term follow-up study indicated that compared with two years of trastuzumab, one year of adjuvant trastuzumab after chemotherapy for HER2-positive BC improved long-term PFS significantly [15]. The gene discussed is ERBB2; the disease is breast cancer.